Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 11/20 | 0.48 |
| ▸ | SLC2A3 | P11169 | 11/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31173657 | 0.92 | SLC2A1 (0.50) | MEN1KMT2ASLC2A1SLC2A3ROCK2 | |
| SCHEMBL27249099 | 0.92 | SLC2A1 (0.50) | MEN1KMT2ASLC2A1SLC2A3ROCK2 | |
| SCHEMBL27248689 | 0.91 | ROCK2 (0.55) | LMNAMAPTKDM4EMEN1HPGD | |
| SCHEMBL27249046 | 0.91 | SLC2A1 (0.48) | LMNAMAPTSLC2A1SLC2A3ROCK2 | |
| SCHEMBL27248960 | 0.90 | ROCK2 (0.46) | LMNAMAPTSLC2A1SLC2A3ROCK2 | |
| SCHEMBL27248887 | 0.90 | ROCK2 (0.46) | LMNAMAPTSLC2A1SLC2A3ROCK2 | |
| SCHEMBL31173666 | 0.90 | ROCK2 (0.49) | SLC2A1SLC2A3ROCK2ROCK1CLK2 | |
| SCHEMBL27248574 | 0.90 | ROCK2 (0.49) | SLC2A1SLC2A3ROCK2ROCK1CLK2 | |
| SCHEMBL31173524 | 0.90 | MEN1 (0.50) | MEN1KMT2ASLC2A1SLC2A3ROCK2 | |
| SCHEMBL27248507 | 0.90 | MEN1 (0.50) | MEN1KMT2ASLC2A1SLC2A3ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360085-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220363648-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | LMNA 4856/4885MAPT 1835/4885KDM4E 2325/4885 |
| US-20220363648-A1 | Glucose Uptake Inhibitors | SLC2A1, SLC2A4, SLC2A2 | LMNA 4856/4885MAPT 1835/4885KDM4E 2325/4885 |
| US-20240360085-A1 | Glucose Uptake Inhibitors | SLC2A3, SLC2A1, SLC2A4 | LMNA 4839/4885MAPT 1717/4885KDM4E 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.